- Home
- BCDA vs NCRA Comparison
BCDA vs NCRA Comparison
Compare BCDA & NCRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- NCRA
- Stock Information
- Founded
- BCDA N/A
- NCRA 2002
- Country
- BCDA United States
- NCRA Taiwan
- Employees
- BCDA N/A
- NCRA N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- NCRA Farming/Seeds/Milling
- Sector
- BCDA Health Care
- NCRA Consumer Staples
- Exchange
- BCDA Nasdaq
- NCRA Nasdaq
- Market Cap
- BCDA 11.5M
- NCRA 11.7M
- IPO Year
- BCDA N/A
- NCRA N/A
- Fundamental
- Price
- BCDA $2.31
- NCRA $0.88
- Analyst Decision
- BCDA Strong Buy
- NCRA
- Analyst Count
- BCDA 1
- NCRA 0
- Target Price
- BCDA $25.00
- NCRA N/A
- AVG Volume (30 Days)
- BCDA 69.0K
- NCRA 17.1K
- Earning Date
- BCDA 03-26-2025
- NCRA 01-01-0001
- Dividend Yield
- BCDA N/A
- NCRA N/A
- EPS Growth
- BCDA N/A
- NCRA N/A
- EPS
- BCDA N/A
- NCRA N/A
- Revenue
- BCDA $71,000.00
- NCRA $20,483,694.00
- Revenue This Year
- BCDA N/A
- NCRA N/A
- Revenue Next Year
- BCDA N/A
- NCRA N/A
- P/E Ratio
- BCDA N/A
- NCRA N/A
- Revenue Growth
- BCDA N/A
- NCRA N/A
- 52 Week Low
- BCDA $1.63
- NCRA $0.70
- 52 Week High
- BCDA $8.85
- NCRA $2.09
- Technical
- Relative Strength Index (RSI)
- BCDA 45.73
- NCRA 46.85
- Support Level
- BCDA $2.27
- NCRA $0.80
- Resistance Level
- BCDA $2.95
- NCRA $0.89
- Average True Range (ATR)
- BCDA 0.26
- NCRA 0.06
- MACD
- BCDA -0.02
- NCRA -0.00
- Stochastic Oscillator
- BCDA 22.89
- NCRA 46.84
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About NCRA Nocera Inc.
Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with expert consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.